<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285024</url>
  </required_header>
  <id_info>
    <org_study_id>CCF 10-916</org_study_id>
    <nct_id>NCT01285024</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty</brief_title>
  <official_title>A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthovita d/b/a Stryker</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stryker Instruments</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, single-center study to assess the&#xD;
      effectiveness of Vitagel, a surgical hemostat, in primary unilateral total hip arthroplasty&#xD;
      (THA). This will be an inter-patient controlled study involving one-hundred-ten subjects.&#xD;
      Vitagel will be used in a randomly selected cohort of fifty-five patients undergoing primary&#xD;
      unilateral THA procedures; a control group of fifty-five patients will not receive Vitagel or&#xD;
      any other hemostatic agent except those that are standard during a primary THA. The study&#xD;
      will evaluate the effectiveness of Vitagel in reducing intra- and post-operative bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitagel Surgical Hemostat is composed of microfibrillar collagen and thrombin in combination&#xD;
      with autologous plasma. It is applied to the surgical site as a sprayable liquid which then&#xD;
      forms a collagen/fibrin gel matrix (containing the patients activated platelets) which&#xD;
      adheres to the bleeding site. This matrix provides hemostasis and facilitates healing.&#xD;
      Vitagel is resorbed in approximately 30 days. It is easily prepared by the OR staff in&#xD;
      minutes and only requires ~10mL's of the patient's blood per Vitagel 4.5ml kit. Compared to&#xD;
      other hemostatic agents on the market today, Vitagel has the advantages of not containing&#xD;
      pooled human donor blood proteins, aprotinin, or tranexamic acid.&#xD;
&#xD;
      Vitagel has been studied in multiple surgical specialties to demonstrate safety and efficacy.&#xD;
      Vitagel was studied in orthopedic procedures, both on iliac crest donor sites and sternal&#xD;
      edges, during its IDE studies for FDA approval. Vitagel was granted broad indications for use&#xD;
      by the FDA in 2000 as an adjunct to hemostasis. It was formerly marketed under the name&#xD;
      CoStasisÂ® Surgical Hemostat, by Cohesion Technologies, Palo Alto, CA.&#xD;
&#xD;
      The use of a surgical hemostat in joint arthroplasty may substantially decrease&#xD;
      post-operative blood loss, which may reduce patient morbidity, length of hospital stay, and&#xD;
      costs by potentially eliminating the need for transfusions and drains.&#xD;
&#xD;
      Total Hip Arthroplasty (THA) is associated with post-operative blood loss and frequently&#xD;
      requires the transfusion of blood products. Increased concern over the risks of blood&#xD;
      transfusion, which include transmission of viral diseases, such as HIV, Hepatitis, and CMV as&#xD;
      well as transfusion reactions, has perpetuated the search for new methods of blood&#xD;
      conservation in orthopedic surgery. There exists considerable variation in the protocols that&#xD;
      are used to optimize hemostasis and minimize post-operative blood loss in patients undergoing&#xD;
      THA. Some methods used include pre-operative hemodilution and hypotensive anesthesia;&#xD;
      however, these methods have associated risks, require careful monitoring, and can prolong the&#xD;
      operative time. Another method used is intra-operative and post-operative salvage of blood&#xD;
      with re-infusion which requires continuous monitoring and is limited to patients who bled&#xD;
      heavily during the initial period following surgery, because the blood should be collected&#xD;
      over a period of not more than six hours. The transfusion of autologous pre-donated blood is&#xD;
      also commonly used in THA surgery. While autologous pre-donated blood is not associated with&#xD;
      the risk of viral disease transmission, the rates of administrative error and bacterial&#xD;
      overgrowth (the factors most frequently associated with immediate post-transfusion deaths)&#xD;
      are comparable with those associated with the use of homologous blood. The collection of&#xD;
      pre-donated blood requires special programs and scheduling. Studies have indicated that the&#xD;
      use of autologous blood transfusions may have little health benefit at considerable costs.&#xD;
&#xD;
      During surgery, meticulous electrocautery, helps minimize both acute blood loss and&#xD;
      post-operative drainage. No uniform guidelines exist regarding the use of post-operative&#xD;
      drains in THA. Some surgeons use drain systems that allow re-infusion of the erythrocytes,&#xD;
      others prefer simple vacuum drains. Still others do not use drains at all. There are&#xD;
      conflicting data regarding the efficacy of closed suction drains. Some studies have shown&#xD;
      that bleeding may be potentiated by suction drainage. Other studies have shown that drains&#xD;
      can lead to complications such as infection, increased blood loss, need for blood&#xD;
      transfusions, breakage in the drain tube, and pain during drain tube removal. Thus, the need&#xD;
      for adequate hemostasis in THA remains apparent.&#xD;
&#xD;
      To date there have been limited published studies on the use of hemostatic agents during THA&#xD;
      procedures. However, even in a relatively low number of patients these studies have shown&#xD;
      that the use of hemostatic agents is a safe and effective means to reduce blood loss and the&#xD;
      need for and rate of blood transfusions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion Requirement</measure>
    <time_frame>intraoperative - 1 week postoperative</time_frame>
    <description>Measure Title: Units of transfusion required</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Hemoglobin Level Change</measure>
    <time_frame>day of surgery - 1 week postoperative</time_frame>
    <description>Total hemoglobin level change from preop to postoperative discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Vitagel used during total hip arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitagel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitagel applied just prior to closure during total hip arthroplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitagel</intervention_name>
    <description>Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
    <arm_group_label>Vitagel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are scheduled for a primary unilateral THA;&#xD;
&#xD;
          -  Are able and willing to provide voluntary written informed consent for participation&#xD;
             in the study;&#xD;
&#xD;
          -  Are between the ages of 18 and 85 at the time of surgery;&#xD;
&#xD;
          -  Are willing to comply with all aspects of the treatment and evaluation period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are known to be sensitive to any materials of bovine origin;&#xD;
&#xD;
          -  Are undergoing a bilateral or revision THA;&#xD;
&#xD;
          -  Patients predonating autologous blood.&#xD;
&#xD;
          -  Patients with a preoperative platelet count of less than 100,000.&#xD;
&#xD;
          -  Patients with a previous history of venous thromboembolism or deep vein thrombosis&#xD;
&#xD;
          -  Medical condition requiring anticoagulation&#xD;
&#xD;
          -  Currently using Coumadin&#xD;
&#xD;
          -  History of Heparin induced thrombocytopenia or Lovenox induced thrombocytopenia&#xD;
&#xD;
          -  Have a history of rheumatoid arthritis or inflammatory arthritis;&#xD;
&#xD;
          -  Peripheral vascular disease.&#xD;
&#xD;
          -  Evidence of bleeding or metabolic - based hemolytic disorder (hemophilia or&#xD;
             anticoagulation use), or hypercoaguable disorder.&#xD;
&#xD;
          -  Patients with history of liver disease. Patients with liver dysfunction from cirrhosis&#xD;
             or hepatitis may have impaired production of factors in the clotting cascade which may&#xD;
             make these individuals more prone to bleed, especially with the use of anticoagulants.&#xD;
             For this reason, these patients will also be excluded from this study if a baseline&#xD;
             INR is greater than 1.3 or APTT greater than 32.4&#xD;
&#xD;
          -  Have a history of failed treatment for abuse of, or are actively abusing, illegal&#xD;
             drugs, solvents, or alcohol;&#xD;
&#xD;
          -  Have a systemic infection or infection at site of surgery;&#xD;
&#xD;
          -  Are a prisoner; and/or&#xD;
&#xD;
          -  Are pregnant or nursing.&#xD;
&#xD;
          -  Condition deemed by physician or medical staff to be non-conducive to patient's&#xD;
             ability to complete the study, or a potential risk to the patient's health and&#xD;
             well-being.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wael K Barsoum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>March 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2016</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Wael Barsoum</investigator_full_name>
    <investigator_title>MD, Chairman of Surgical Operations</investigator_title>
  </responsible_party>
  <keyword>total hip arthroplasty</keyword>
  <keyword>transfusion</keyword>
  <keyword>hemostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>No Vitagel used during total hip arthroplasty</description>
        </group>
        <group group_id="P2">
          <title>Vitagel</title>
          <description>Vitagel applied just prior to closure during total hip arthroplasty&#xD;
Vitagel: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>No Vitagel used during total hip arthroplasty</description>
        </group>
        <group group_id="B2">
          <title>Vitagel</title>
          <description>Vitagel applied just prior to closure during total hip arthroplasty&#xD;
Vitagel: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="9.4"/>
                    <measurement group_id="B2" value="58.2" spread="11.8"/>
                    <measurement group_id="B3" value="58.0" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="6.7"/>
                    <measurement group_id="B2" value="32.6" spread="7.0"/>
                    <measurement group_id="B3" value="31.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transfusion Requirement</title>
        <description>Measure Title: Units of transfusion required</description>
        <time_frame>intraoperative - 1 week postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No Vitagel used during total hip arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Vitagel</title>
            <description>Vitagel applied just prior to closure during total hip arthroplasty&#xD;
Vitagel: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion Requirement</title>
          <description>Measure Title: Units of transfusion required</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.5"/>
                    <measurement group_id="O2" value="2.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hemoglobin Level Change</title>
        <description>Total hemoglobin level change from preop to postoperative discharge.</description>
        <time_frame>day of surgery - 1 week postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No Vitagel used during total hip arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Vitagel</title>
            <description>Vitagel applied just prior to closure during total hip arthroplasty&#xD;
Vitagel: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hemoglobin Level Change</title>
          <description>Total hemoglobin level change from preop to postoperative discharge.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.1"/>
                    <measurement group_id="O2" value="4.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No Vitagel used during total hip arthroplasty</description>
        </group>
        <group group_id="E2">
          <title>Vitagel</title>
          <description>Vitagel applied just prior to closure during total hip arthroplasty&#xD;
Vitagel: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound drainiage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PE/DVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention/Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Edema with pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>President and CEO Cleveland Clinic Florida</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-7515</phone>
      <email>barsouw@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

